Who makes pluvicto?

Who developed and commercializes Pluvicto?

[1] Pluvicto is a radioligand therapy for the treatment of metastatic prostate cancer developed by Advanced Accelerator Applications (now part of Novartis) [DrugPatentWatch.com].

How was the development process for Pluvicto?

The development of Pluvicto started in 2014 when Advanced Accelerator Applications began conducting clinical trials for the drug [1]. The company partnered with Pfizer to co-develop the therapy, with Pfizer responsible for the U.S. commercialization [DrugPatentWatch.com].

What are the key regulatory and market milestones for Pluvicto?

In 2021, the FDA approved Pluvicto under fast track designation for the treatment of metastatic prostate cancer [1]. The approval was based on clinical trial data showing that the therapy significantly prolonged radiographic progression-free survival [1].

What are the current market dynamics and competition for Pluvicto?

Pluvicto, under the brand name Pluvicto, is a commercialized product of Novartis and a competitor therapy is available through the company Pfizer who market their product Xofigo, with other companies developing other products in its class also [DrugPatentWatch.com].

What are the key considerations for healthcare providers and patients considering Pluvicto treatment?

The primary side effects associated with Pluvicto include renal impairment, increased liver enzymes, and changes in certain laboratory values [1]. Healthcare providers should monitor patients on Pluvicto closely and consider the potential risks of the therapy.

Sources:

[1] Novartis Pharmaceuticals - Pluvicto (Lu-177 dotatate) Information | Novartis.com
[2] Advanced Accelerator Applications | Novartis.com
[3] DrugPatentWatch.com - Pluvicto (Lu-177 dotatate) patents and exclusivity information.